Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2003 | 2 |
2005 | 1 |
2009 | 2 |
2024 | 0 |
Search Results
5 results
Results by year
Filters applied: . Clear all
Page 1
Blood-brain barrier-specific properties of a human adult brain endothelial cell line.
FASEB J. 2005 Nov;19(13):1872-4. doi: 10.1096/fj.04-3458fje. Epub 2005 Sep 1.
FASEB J. 2005.
PMID: 16141364
Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis.
Chilcott J, McCabe C, Tappenden P, O'Hagan A, Cooper NJ, Abrams K, Claxton K, Miller DH; Cost Effectiveness of Multiple Sclerosis Therapies Study Group.
Chilcott J, et al.
BMJ. 2003 Mar 8;326(7388):522; discussion 522. doi: 10.1136/bmj.326.7388.522.
BMJ. 2003.
PMID: 12623909
Free PMC article.
RESULTS: The base case cost per quality adjusted life year gained by using any of the four treatments ranged from pound 42,000 (66,469 dollars; 61,630 euro) to pound 98,000 based on efficacy information in the public domain. ...
RESULTS: The base case cost per quality adjusted life year gained by using any of the four treatments ranged from pound 42,000 (66,469 dolla …
Item in Clipboard
Expression of chemokines and their receptors by human brain endothelium: implications for multiple sclerosis.
Subileau EA, Rezaie P, Davies HA, Colyer FM, Greenwood J, Male DK, Romero IA.
Subileau EA, et al.
J Neuropathol Exp Neurol. 2009 Mar;68(3):227-40. doi: 10.1097/NEN.0b013e318197eca7.
J Neuropathol Exp Neurol. 2009.
PMID: 19225413
Free article.
Item in Clipboard
Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial.
Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A; UK MS Research Group.
Zajicek J, et al.
Lancet. 2003 Nov 8;362(9395):1517-26. doi: 10.1016/S0140-6736(03)14738-1.
Lancet. 2003.
PMID: 14615106
Clinical Trial.
METHODS: We did a randomised, placebo-controlled trial, to which we enrolled 667 patients with stable multiple sclerosis and muscle spasticity. 630 participants were treated at 33 UK centres with oral cannabis extract (n=211), Delta9-tetrahydrocannabinol (Delta9-THC; n=206 …
METHODS: We did a randomised, placebo-controlled trial, to which we enrolled 667 patients with stable multiple sclerosis and muscle spastici …
Item in Clipboard
Different white matter lesion characteristics correlate with distinct grey matter abnormalities on magnetic resonance imaging in secondary progressive multiple sclerosis.
Furby J, Hayton T, Altmann D, Brenner R, Chataway J, Smith KJ, Miller DH, Kapoor R.
Furby J, et al.
Mult Scler. 2009 Jun;15(6):687-94. doi: 10.1177/1352458509103176. Epub 2009 May 12.
Mult Scler. 2009.
PMID: 19435748
Item in Clipboard
Cite
Cite